We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-15.46%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$761M
AUM Growth
+$81M
Cap. Flow
+$243M
Cap. Flow %
31.93%
Top 10 Hldgs %
59.91%
Holding
63
New
13
Increased
16
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$33.1M
2
DXCM icon
DexCom
DXCM
+$19.8M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$19.4M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$16.7M
5
TSRO
TESARO, Inc.
TSRO
+$16.2M

Top Sells

Rank Stock Value
1
CORI
Corium International, Inc.
CORI
+$22.5M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$17.1M
3
PACB icon
Pacific Biosciences
PACB
+$13.5M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$11.8M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.04M

Sector Composition

Rank Sector Weight
1 Healthcare 55.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IART icon
26
Integra LifeSciences
IART
$1.5B
$8.87M 1.17%
196,572
– –
MRTX
27
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.48M 1.12%
200,000
-157,672
-44% -$6.28M
XENT
28
DELISTED
Intersect ENT, Inc
XENT
$8.11M 1.07%
287,900
+53,700
+23% +$1.57M
AVDL
29
DELISTED
Avadel Pharmaceuticals
AVDL
$8.01M 1.05%
3,102,673
+309,900
+11% +$1.05M
SRRA
30
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.44M 0.85%
122,008
+19,749
+19% +$1.26M
ALXN
31
DELISTED
Alexion Pharmaceuticals
ALXN
$5.71M 0.75%
+58,700
New +$6.94M
SSKN
32
DELISTED
Strata Skin Sciences
SSKN
$5.65M 0.74%
217,136
-1,000
-0.5% -$28.6K
VRAY
33
DELISTED
ViewRay, Inc.
VRAY
$5.26M 0.69%
866,500
+616,500
+247% +$4.62M
SLGL icon
34
Sol-Gel Technologies
SLGL
$272M
$5.1M 0.67%
84,770
– –
BHVN
35
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$4.78M 0.63%
+129,300
New +$4.66M
LIVN icon
36
LivaNova
LIVN
$4.43B
$4.67M 0.61%
51,000
– –
OPTN
37
DELISTED
OptiNose
OPTN
$4.41M 0.58%
+47,373
New +$6.77M
NEOS
38
DELISTED
Neos Therapeutics, Inc
NEOS
$4.32M 0.57%
+2,618,819
New +$7.35M
RVLP
39
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
$4.1M 0.54%
+528,571
New +$4.23M
TLGT
40
DELISTED
Teligent, Inc
TLGT
$3.87M 0.51%
282,338
-22,947
-8% -$600K
TNDM icon
41
Tandem Diabetes Care
TNDM
$1.17B
$3.38M 0.44%
89,100
-483,979
-84% -$17.1M
VCEL icon
42
Vericel Corp
VCEL
$2.38B
$3.31M 0.43%
190,000
+57,400
+43% +$859K
HRTX icon
43
Heron Therapeutics
HRTX
$89.1M
$3.09M 0.41%
119,294
-171,919
-59% -$4.73M
KALV
44
DELISTED
KalVista Pharmaceuticals
KALV
$2.83M 0.37%
143,129
-6,871
-5% -$138K
DOVA
45
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$2.67M 0.35%
+351,800
New +$5.66M
KALA icon
46
KALA BIO
KALA
$14.4M
$1.66M 0.22%
136
-3
-2% -$52K
EIGR
47
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.46M 0.19%
+4,777
New +$1.54M
ACGN
48
DELISTED
Aceragen Inc
ACGN
$1.35M 0.18%
28,652
-8,405
-23% -$966K
NVLN
49
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$1.03M 0.14%
1,229,301
-719,253
-37% -$812K
ATEC icon
50
Alphatec Holdings
ATEC
$1.31B
$1.03M 0.14%
449,585
-220,227
-33% -$620K
1
2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2018 Portfolio in Review

As of Q4 2018, Broadfin Capital held 63 positions worth $761M, up 12% from $680M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Broadfin Capital deployed $243M of net new capital in Q4 2018, opening 13 new positions and adding to 16 existing holdings. Its largest new stake was NEVRO CORP.: 744,415 shares worth $28.9M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 73% a quarter earlier.

On the sell side, the largest reduction was Tandem Diabetes Care, an estimated $17.1M trimmed.

  • Broadfin Capital's largest Q4 2018 buy was NEVRO CORP.: 744,415 shares worth $28.9M.
  • Broadfin Capital added most to DexCom in Q4 2018, an estimated $19.8M increase.
  • Broadfin Capital's biggest Q4 2018 reduction was Tandem Diabetes Care, cutting an estimated $17.1M.
  • Broadfin Capital fully exited Corium International, Inc. in Q4 2018, selling an estimated $22.5M.
  • Broadfin Capital's ten largest holdings make up 60% of its $761M portfolio in Q4 2018.
  • Broadfin Capital opened 13 new positions and closed 13 in Q4 2018.
  • Broadfin Capital's portfolio value rose 12% quarter-over-quarter to $761M.

Based on Broadfin Capital's 13F filing for Q4 2018, filed 14 Feb 2019.